Angiotensin Converting Enzymes (ACE) Inhibitors Market - Report Analysis, 2022 - 2028
Description
Angiotensin Converting Enzymes (ACE) Inhibitors Market - Report Analysis, 2022 - 2028
Angiotensin converting enzymes (ACE) inhibitors act by inhibiting the angiotensin converting enzyme (ACE), which is an important component of renin angiotensin system. ACE inhibitors reduce the formation of angiotensin II and facilitate the dilation of blood vessels as well as reduce blood pressure. Angiotensin converting enzyme inhibitors also reduce blood pressure in kidneys. Angiotensin converting enzymes inhibitors (ACE) are effective for the treatment of congestive heart failure, stroke, and high blood pressure. However, overdose of ACE inhibitors may cause kidney failure, allergic reactions, angioedema, and neutropenia.
Market Dynamics
Increasing research and development activities related to study of ACE inhibitors is expected to boost the angiotensin converting enzymes (ACE) inhibitors market growth. For instance, in February 2016, Monia Lorini, in collaboration with Istituto Di Ricerche Farmacologiche Mario Negri initiated clinical phase II study of ACE inhibitors (Lisinopril) for the treatment of extracapillary glomerulonephritis. This study is for evaluating drug safety and efficacy on the patients. It is expected to complete in December 2019.
Furthermore, in June 2014, Cardiology Research UBC initiated clinical trial phase IV to study the effects of statin including Rosuvastatin and Ramipril - angiotensin converting enzymes inhibitors such as Ramipril on coronary flow reserve and microcirculatory resistance in patients with coronary artery dissection. This study is expected to complete in June 2021.
Overdose of angiotensin converting enzyme (ACE) inhibitors is a major factor restraining growth of the ACE inhibitors market. Overdose of ACE inhibitors may lead to various side effects such as dry cough, hyperkalemia (increased blood potassium level), dizziness, headache, and fatigue. Overdose of ACE inhibitors may also cause cancer. For instance, in October 2018, according to Medical Press (medical center in Melbourne, Australia), angiotensin converting enzymes (ACE) inhibitors are used for the treatment of high blood pressure. However, overdose of ACE inhibitors can increases the risk of lung cancer in patients. These drugs are responsible for the excessive production of bradykinin in the lungs. Excessive bradykinin is the main cause of lung cancer.
Key features of the study:
This report provides in-depth analysis of the angiotensin converting enzymes (ACE) inhibitors market size (US$ Mn) and cumulative annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global angiotensin converting enzymes (ACE) inhibitors market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include, Pfizer, Inc., AstraZeneca, Novartis AG, Daiichi Sankyo Company, Ltd., United Therapeutics Corporation, Sanofi S.A., Johnson & Johnson Services, Inc., Merck KGaA, Takeda Pharmaceutical Company and Bayer AG.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global angiotensin converting enzymes (ACE) inhibitors market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for angiotensin converting enzymes (ACE) inhibitors market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs:
Benazepril
Perindopril
Trandolapril
Captopril
Enalaopril
Lisinopril
Ramipril
Others
Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Application:
Hypertension
Coronary artery disease
Heart failure
Chronic kidney disease
Scleroderma
Migraine
Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Angiotensin Converting Enzymes (ACE) Inhibitors market, By Region:
North America
By Country:
U.S.
Canada
By Drugs:
Benazepril
Perindopril
Trandolapril
Captopril
Enalaopril
Lisinopril
Ramipril
Others
By Application
Hypertension
Coronary artery disease
Heart failure
Chronic kidney diseases
Scleroderma
Migraine
By Distribution Channels:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drugs:
Benazepril
Perindopril
Trandolapril
Captopril
Enalaopril
Lisinopril
Ramipril
Others
By Application
Hypertension
Coronary artery disease
Heart failure
Chronic kidney disease
Scleroderma
Migraine
By Distribution Channels:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drugs:
Benazepril
Perindopril
Trandolapril
Captopril
Enalaopril
Lisinopril
Ramipril
Others
By Application:
Hypertension
Coronary artery disease
Heart failure
Chronic kidney disease
Scleroderma
Migraine
By Distribution Channels:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drugs:
Benazepril
Perindopril
Trandolapril
Captopril
Enalaopril
Lisinopril
Ramipril
Others
By Application
Hypertension
Coronary artery disease
Heart failure
Chronic kidney disease
Scleroderma
Migraine
By Distribution Channels:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drugs:
Benazepril
Perindopril
Trandolapril
Captopril
Enalaopril
Lisinopril
Ramipril
Others
By Application:
Hypertension
Coronary artery disease
Heart failure
Chronic kidney disease
Scleroderma
Migraine
By Distribution Channels:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Drugs:
Benazepril
Perindopril
Trandolapril
Captopril
Enalaopril
Lisinopril
Ramipril
Others
By Application:
Hypertension
Coronary artery disease
Heart failure
Chronic kidney disease
Scleroderma
Migraine
By Distribution Channels:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Pfizer, Inc.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
AstraZeneca Pharmaceutical Company
Novartis AG
Daiichi Sankyo Company, Ltd.
United Therapeutics Corporation
Sanofi S.A.
Johnson & Johnson Services, Inc.
Merck KGaA
Takeda Pharmaceutical Company
Bayer AG
“*” marked represents similar segmentation in other categories in the respective section.
Angiotensin converting enzymes (ACE) inhibitors act by inhibiting the angiotensin converting enzyme (ACE), which is an important component of renin angiotensin system. ACE inhibitors reduce the formation of angiotensin II and facilitate the dilation of blood vessels as well as reduce blood pressure. Angiotensin converting enzyme inhibitors also reduce blood pressure in kidneys. Angiotensin converting enzymes inhibitors (ACE) are effective for the treatment of congestive heart failure, stroke, and high blood pressure. However, overdose of ACE inhibitors may cause kidney failure, allergic reactions, angioedema, and neutropenia.
Market Dynamics
Increasing research and development activities related to study of ACE inhibitors is expected to boost the angiotensin converting enzymes (ACE) inhibitors market growth. For instance, in February 2016, Monia Lorini, in collaboration with Istituto Di Ricerche Farmacologiche Mario Negri initiated clinical phase II study of ACE inhibitors (Lisinopril) for the treatment of extracapillary glomerulonephritis. This study is for evaluating drug safety and efficacy on the patients. It is expected to complete in December 2019.
Furthermore, in June 2014, Cardiology Research UBC initiated clinical trial phase IV to study the effects of statin including Rosuvastatin and Ramipril - angiotensin converting enzymes inhibitors such as Ramipril on coronary flow reserve and microcirculatory resistance in patients with coronary artery dissection. This study is expected to complete in June 2021.
Overdose of angiotensin converting enzyme (ACE) inhibitors is a major factor restraining growth of the ACE inhibitors market. Overdose of ACE inhibitors may lead to various side effects such as dry cough, hyperkalemia (increased blood potassium level), dizziness, headache, and fatigue. Overdose of ACE inhibitors may also cause cancer. For instance, in October 2018, according to Medical Press (medical center in Melbourne, Australia), angiotensin converting enzymes (ACE) inhibitors are used for the treatment of high blood pressure. However, overdose of ACE inhibitors can increases the risk of lung cancer in patients. These drugs are responsible for the excessive production of bradykinin in the lungs. Excessive bradykinin is the main cause of lung cancer.
Key features of the study:
This report provides in-depth analysis of the angiotensin converting enzymes (ACE) inhibitors market size (US$ Mn) and cumulative annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global angiotensin converting enzymes (ACE) inhibitors market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include, Pfizer, Inc., AstraZeneca, Novartis AG, Daiichi Sankyo Company, Ltd., United Therapeutics Corporation, Sanofi S.A., Johnson & Johnson Services, Inc., Merck KGaA, Takeda Pharmaceutical Company and Bayer AG.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global angiotensin converting enzymes (ACE) inhibitors market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for angiotensin converting enzymes (ACE) inhibitors market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs:
Benazepril
Perindopril
Trandolapril
Captopril
Enalaopril
Lisinopril
Ramipril
Others
Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Application:
Hypertension
Coronary artery disease
Heart failure
Chronic kidney disease
Scleroderma
Migraine
Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Angiotensin Converting Enzymes (ACE) Inhibitors market, By Region:
North America
By Country:
U.S.
Canada
By Drugs:
Benazepril
Perindopril
Trandolapril
Captopril
Enalaopril
Lisinopril
Ramipril
Others
By Application
Hypertension
Coronary artery disease
Heart failure
Chronic kidney diseases
Scleroderma
Migraine
By Distribution Channels:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drugs:
Benazepril
Perindopril
Trandolapril
Captopril
Enalaopril
Lisinopril
Ramipril
Others
By Application
Hypertension
Coronary artery disease
Heart failure
Chronic kidney disease
Scleroderma
Migraine
By Distribution Channels:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drugs:
Benazepril
Perindopril
Trandolapril
Captopril
Enalaopril
Lisinopril
Ramipril
Others
By Application:
Hypertension
Coronary artery disease
Heart failure
Chronic kidney disease
Scleroderma
Migraine
By Distribution Channels:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drugs:
Benazepril
Perindopril
Trandolapril
Captopril
Enalaopril
Lisinopril
Ramipril
Others
By Application
Hypertension
Coronary artery disease
Heart failure
Chronic kidney disease
Scleroderma
Migraine
By Distribution Channels:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drugs:
Benazepril
Perindopril
Trandolapril
Captopril
Enalaopril
Lisinopril
Ramipril
Others
By Application:
Hypertension
Coronary artery disease
Heart failure
Chronic kidney disease
Scleroderma
Migraine
By Distribution Channels:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Drugs:
Benazepril
Perindopril
Trandolapril
Captopril
Enalaopril
Lisinopril
Ramipril
Others
By Application:
Hypertension
Coronary artery disease
Heart failure
Chronic kidney disease
Scleroderma
Migraine
By Distribution Channels:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Pfizer, Inc.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
AstraZeneca Pharmaceutical Company
Novartis AG
Daiichi Sankyo Company, Ltd.
United Therapeutics Corporation
Sanofi S.A.
Johnson & Johnson Services, Inc.
Merck KGaA
Takeda Pharmaceutical Company
Bayer AG
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
163 Pages
- 1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drugs
- Market Snippet, By Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Pipeline Analysis
- Epidemiology
- Historical Overview
- Merger and Acquisition
- Regulatory Scenario
- PEST Analysis
- 4. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Drugs, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Benazepril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Perindopril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Trandolapril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Captopril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Enalaopril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Lisinopril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Ramipril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- 5. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Application, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Hypertension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Coronary artery disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Heart failure
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Chronic kidney disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Scleroderma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Migraine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- 6. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Distribution Channel, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- 7. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Region, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, By Region, 2017 - 2028
- Regional Trends
- North America
- Market Size and Forecast, By Drugs, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Drugs, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drugs, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Drugs, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Drugs, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channels, 2017 - 2028, (US$ Million
- Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Million)
- North Africa
- Central Africa
- South Africa
- Middle East
- Market Size and Forecast, By Drugs, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- GCC Countries
- Israel
- Rest of Middle East
- 8. Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- AstraZeneca Pharmaceutical Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Daiichi Sankyo Company, Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- United Therapeutics Corporation
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Sanofi S.A.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Johnson & Johnson Services, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Merck KGaA
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Takeda Pharmaceutical Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Bayer AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Analyst Views
- 9. Section
- References
- Research Methodology
- About us and Sales Contact
- *Browse 29 market data tables and 25 figures on “Angiotensin Converting Enzymes (ACE) Inhibitors Market” - Global forecast to 2028”.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
